Wincef Vial 1gm

Indication :

Wincef is indicated in the treatment of infections caused by bacteria that are cefepime sensitive: - lower respiratory tract infections, including nosocomial pneumonia and community acquired pnemonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis; - uncomplicated and complicated urinary tract infections, including pyelonephritis; -skin and subcutaneous infections; - intra-abdominal infections, including peritonitis and biliary tract infections; -gynaecological infections; - bacterial meningitis in infants and children; - In combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; - Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Composition :

Wincef 0.5 g powder for solution for injection or infusion: each vial contains: sterile mixture of Cefepime (as HCL) with L-Arginine. Active ingredients: sterile mix. of cefepime HCL and L-Arginine which contains Cefepime HCL 0.594 g (Eq. to Cefepime 0.5 g and L-Arginine 0.363 g) 0.957 g.

Wincef 1 g powder for solution for injection or infusion: each vial contains: sterile mixture of cefepime (as HCL) with LArginine. Active Ingredients: sterile mix. Of Cefepime HCI and L-Arginine contains Cefepime HCL 1.189 g (Eq. to Cefepime 0.725 g) 1.914 g. Wincef 2 g powder for solution for injection or infusion: each vial contains: sterile mixture of cefepime (as HCL) with LArginine. Active ingredients: sterile mix. Of Cefepime and L-Arginine contains Cefepime HCL 2.378g (Eq. to Cefepime 2.0 g and L-Arginine 1.45 g) 3.828 g